FDA
-
-
-
-
-
-
-
Neuronetics names new CFO, promotes executive, and loses legal chief
-
-
-
-
-
-
-
AXGN reports preliminary Q4 revenue of $59.9 million, up 21%
-
-
-
-
-
-
-
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
-
-
-
-
-
-
-
Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft
-
-
-
-
-
-
-
Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update
-
-
-
-
-
-
-
AxoGen (AXGN) Initiates Rolling Submission of BLA for Avance Nerve Graft
-
-
-
-
-
-
-
Axogen, Inc. Reports 2023 First Quarter Financial Results
-
330,737 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

